Table 1 Cytotoxic activities of β-carboline derivatives in vitro (IC₅₀, μM^a).

Cmpd	Hela^b	Bel-7402	HepG2	BGC-823	A549	A375	HT-29	769-P	786-0	KB	DLD1	HCT116	RKO
2a	139	190	171	>200	36.7	71.4	62.9	7.83	37.5	>200	>200	56.1	74.2
2b	142	118	60.5	167	47.1	42.2	21.3	25.6	12.9	29.5	>200	136	89.6
2c	50.5	34.6	32.2	66.2	12.8	23.9	27.8	5.72	14.4	24.6	39.3	43.7	32.6
2d	88.8	29.7	66.0	141	38.1	59.5	>200	25.2	67.4	30.1	30.8	31.5	28.5
2e	>200	>200	186	>200	127	>200	>200	123	92.3	58.9	95.2	123	78.6
2f	92.3	>200	92.9	>200	78.6	4.32	54.3	62.9	89.1	150	170	63.5	126
2g	>200	>200	197	>200	>200	>200	>200	>200	>200	>200	>200	>200	>200
2h	>200	>200	>200	>200	>200	>200	>200	>200	>200	>200	>200	>200	>200
2i	>200	>200	>200	>200	>200	>200	>200	>200	>200	>200	>200	>200	>200
2j	89.6	62.8	75.3	96.4	136	125	54.8	114	63.5	87.6	123	69.2	78.6
3a	32.1	22.5	9.63	22.9	10.8	28.2	9.41	4.90	10.0	17.9	30.8	8.52	5.40
3b	6.74	7.72	6.71	21.8	9.12	8.43	7.81	5.12	11.2	3.93	9.74	1.71	2.93
3c	4.52	2.92	2.11	0.46	3.93	0.68	4.32	4.61	3.22	0.93	1.63	3.82	3.21
3d	6.81	1.64	8.92	7.12	3.42	7.31	3.20	8.22	4.61	2.71	7.94	1.62	4.24
3e	14.4	17.9	5.23	14.8	7.62	25.3	10.5	19.8	28.6	15.4	21.2	5.70	4.52
3f	2.90	1.53	1.31	4.10	2.83	4.52	2.51	3.12	2.73	2.41	6.92	1.52	2.10
3g	3.20	2.14	3.42	8.02	3.03	2.92	8.24	2.53	1.72	7.94	6.80	2.62	2.63
Cisplatin	6.4	12.8	13.6	13.2	6.84	9.46	25.4	16.8	11.2	8.62	12.6	6.31	7.62

^aCytotoxicity as IC₅₀ for each cell line, is the concentration of compound which reduced by 50% the optical density of treated cells with respect to untreated cells using the CCK8 assay.
^bCell line include (Hela), liver carcinoma (Bel-7402 and HepG2), gastric carcinoma (BGC-823), non-small cell lung carcinoma (A549), malignant melanoma (A375), colon carcinoma (HT-29), renal carcinoma (769-P and 786-0), epidermoid carcinoma of the nasopharynx (KB) and colorectal carcinoma (DLD, HCT116 and RKO).
^cData represent the mean values of three independent determinations.

Quick links

Search